IL3 and acute myeloid leukemia: The 7G3 mAb was humanized and affinity-matured and was engineered in its Fc-domain to improve its cytotoxicity against AML cells: the antibody thus modified was called CSL362 and displayed the same capacity to neutralize IL-3, but displayed increased antibody-dependent cytotoxicity against AML cells compared to 7G3 [116].